Dark | Light
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

# ![@StreetCred2017 Avatar](https://lunarcrush.com/gi/w:26/cr:twitter::949761349197864960.png) @StreetCred2017 @StreetCred2018

@StreetCred2018 posts on X about $amgn, $ifrx, rates, upside the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours.

### Engagements: XX [#](/creator/twitter::949761349197864960/interactions)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::949761349197864960/c:line/m:interactions.svg)

- X Week XXX -XX%
- X Month XXXXXX +53%
- X Months XXXXXX -XX%
- X Year XXXXXXXXX +106%

### Mentions: X [#](/creator/twitter::949761349197864960/posts_active)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::949761349197864960/c:line/m:posts_active.svg)

- X Week XX -XX%
- X Month XX +41%
- X Months XXX -XX%
- X Year XXX +59%

### Followers: XXX [#](/creator/twitter::949761349197864960/followers)
![Followers Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::949761349197864960/c:line/m:followers.svg)

- X Week XXX +0.36%
- X Month XXX +0.61%
- X Months XXX +13%
- X Year XXX -XXXX%

### CreatorRank: undefined [#](/creator/twitter::949761349197864960/influencer_rank)
![CreatorRank Line Chart](https://lunarcrush.com/gi/w:600/cr:twitter::949761349197864960/c:line/m:influencer_rank.svg)

### Social Influence [#](/creator/twitter::949761349197864960/influence)
---

**Social category influence**
[stocks](/list/stocks)  XXXX% [finance](/list/finance)  XXXX%

**Social topic influence**
[$amgn](/topic/$amgn) 3.13%, [$ifrx](/topic/$ifrx) 2.08%, [rates](/topic/rates) 1.04%, [upside](/topic/upside) 1.04%, [finance](/topic/finance) 1.04%, [wld](/topic/wld) 1.04%, [versa](/topic/versa) 1.04%, [insurance](/topic/insurance) XXXX%

**Top accounts mentioned or mentioned by**
[@quick2smile](/creator/undefined) [@o248528307](/creator/undefined) [@3in5saved](/creator/undefined) [@maximusholla](/creator/undefined) [@rdd147](/creator/undefined) [@dogtor01416800](/creator/undefined) [@kobeissiletter](/creator/undefined) [@biopharmiq](/creator/undefined) [@semodough](/creator/undefined) [@biovalues](/creator/undefined) [@peterschiff](/creator/undefined) [@elonmusk](/creator/undefined) [@billackman](/creator/undefined) [@realdonaldtrump](/creator/undefined) [@zerohedge](/creator/undefined) [@cdcdirector](/creator/undefined) [@cdcgov](/creator/undefined) [@fdacderdirector](/creator/undefined) [@usdafoodsafety](/creator/undefined) [@biotechsanya2](/creator/undefined)

**Top assets mentioned**
[Amgen, Inc. (AMGN)](/topic/$amgn)
### Top Social Posts [#](/creator/twitter::949761349197864960/posts)
---
Top posts by engagements in the last XX hours

"@Quick2smile @ANKITSH85153215 Interesting and I think Inflarx did same thing w cSCC At end of the day it (C5a antagonist) may wind up being used in combination w some chemo agent. $AMGN $IFRX #PancreaticCancer needs anything that improves XX% survival rates. Compassionate use"  
[X Link](https://x.com/StreetCred2017/status/1975181788009115894) [@StreetCred2017](/creator/x/StreetCred2017) 2025-10-06T12:50Z XXX followers, XXX engagements


"@biotechsanya2 Also avacopan is approved for AAV so not exactly a failure for $AMGN but assume youre talking about the P1 Inflarx comparison of INF904 v avacopan"  
[X Link](https://x.com/StreetCred2017/status/1978589499119604212) [@StreetCred2017](/creator/x/StreetCred2017) 2025-10-15T22:31Z XXX followers, XXX engagements


"@biotechsanya2 Not sure if this helps comparing $AMGN avacopan v INF904 $IFRX"  
[X Link](https://x.com/StreetCred2017/status/1978605196461695371) [@StreetCred2017](/creator/x/StreetCred2017) 2025-10-15T23:33Z XXX followers, XXX engagements


"@Investorclimber @Biotech_AI Gents - any best guess on upside with only X of X showing promise VS both CSU Yes HS -No: or visa versa Guggenheim called 5-10x but seems overly optimistic given need to finance P2b but both wld show pipeline potential. Also partner needed"  
[X Link](https://x.com/StreetCred2017/status/1978425820487069859) [@StreetCred2017](/creator/x/StreetCred2017) 2025-10-15T11:40Z XXX followers, XXX engagements


"@3in5saved Still we need fda to say yes - or insurance willing to pay to use Gohibic off label -"  
[X Link](https://x.com/StreetCred2017/status/1979586654152098003) [@StreetCred2017](/creator/x/StreetCred2017) 2025-10-18T16:33Z XXX followers, XX engagements

[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@StreetCred2017 Avatar @StreetCred2017 @StreetCred2018

@StreetCred2018 posts on X about $amgn, $ifrx, rates, upside the most. They currently have XXX followers and XX posts still getting attention that total XX engagements in the last XX hours.

Engagements: XX #

Engagements Line Chart

  • X Week XXX -XX%
  • X Month XXXXXX +53%
  • X Months XXXXXX -XX%
  • X Year XXXXXXXXX +106%

Mentions: X #

Mentions Line Chart

  • X Week XX -XX%
  • X Month XX +41%
  • X Months XXX -XX%
  • X Year XXX +59%

Followers: XXX #

Followers Line Chart

  • X Week XXX +0.36%
  • X Month XXX +0.61%
  • X Months XXX +13%
  • X Year XXX -XXXX%

CreatorRank: undefined #

CreatorRank Line Chart

Social Influence #


Social category influence stocks XXXX% finance XXXX%

Social topic influence $amgn 3.13%, $ifrx 2.08%, rates 1.04%, upside 1.04%, finance 1.04%, wld 1.04%, versa 1.04%, insurance XXXX%

Top accounts mentioned or mentioned by @quick2smile @o248528307 @3in5saved @maximusholla @rdd147 @dogtor01416800 @kobeissiletter @biopharmiq @semodough @biovalues @peterschiff @elonmusk @billackman @realdonaldtrump @zerohedge @cdcdirector @cdcgov @fdacderdirector @usdafoodsafety @biotechsanya2

Top assets mentioned Amgen, Inc. (AMGN)

Top Social Posts #


Top posts by engagements in the last XX hours

"@Quick2smile @ANKITSH85153215 Interesting and I think Inflarx did same thing w cSCC At end of the day it (C5a antagonist) may wind up being used in combination w some chemo agent. $AMGN $IFRX #PancreaticCancer needs anything that improves XX% survival rates. Compassionate use"
X Link @StreetCred2017 2025-10-06T12:50Z XXX followers, XXX engagements

"@biotechsanya2 Also avacopan is approved for AAV so not exactly a failure for $AMGN but assume youre talking about the P1 Inflarx comparison of INF904 v avacopan"
X Link @StreetCred2017 2025-10-15T22:31Z XXX followers, XXX engagements

"@biotechsanya2 Not sure if this helps comparing $AMGN avacopan v INF904 $IFRX"
X Link @StreetCred2017 2025-10-15T23:33Z XXX followers, XXX engagements

"@Investorclimber @Biotech_AI Gents - any best guess on upside with only X of X showing promise VS both CSU Yes HS -No: or visa versa Guggenheim called 5-10x but seems overly optimistic given need to finance P2b but both wld show pipeline potential. Also partner needed"
X Link @StreetCred2017 2025-10-15T11:40Z XXX followers, XXX engagements

"@3in5saved Still we need fda to say yes - or insurance willing to pay to use Gohibic off label -"
X Link @StreetCred2017 2025-10-18T16:33Z XXX followers, XX engagements

@StreetCred2017
/creator/twitter::StreetCred2017